BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
11/17/2021 12:02:34 PM | Browse: 468 | Download: 946
 |
Received |
|
2021-06-28 14:14 |
|
Peer-Review Started |
|
2021-06-28 14:17 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2021-07-31 04:36 |
|
Revised |
|
2021-08-22 19:02 |
|
Second Decision |
|
2021-09-14 03:39 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2021-09-17 02:44 |
|
Articles in Press |
|
2021-09-17 02:44 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2021-10-21 17:40 |
|
Typeset the Manuscript |
|
2021-11-15 06:30 |
|
Publish the Manuscript Online |
|
2021-11-17 12:02 |
| ISSN |
2220-3192 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Pharmacology & Pharmacy |
| Manuscript Type |
Review |
| Article Title |
Therapeutics for treatment of SARS-CoV2 (COVID-19): A safety perspective
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Joshua Davis, Ugochukwu Umeh and Rand Saba |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Joshua Davis, MD, Attending Doctor, Department of Emergency Medicine, Vituity, 929 N. St. Francis Avenue, Wichita, KS 67214, United States. jjvwd@udel.edu |
| Key Words |
COVID-19; Coronavirus; SARS-CoV2; SARS; Drug safety; Pharmacotherapy |
| Core Tip |
The novel coronavirus disease 2019 (COVID-19) has radically changed the approach to healthcare and public health in the last year. Over 100 million people worldwide have been affected. Dexamethasone appears to be the most efficacious drug for appropriately selected patients with COVID-19 (i.e., those requiring supplemental oxygen). Remdesivir may reduce length of hospitalization with mild side effects. While they do not have enough evidence to be recommended at this time, ivermectin and zinc should be studied further for early illness and interferon and interleukin blockade should be studied for critical illness. Hydroxychloroquine/chloroquine, azithromycin, and vitamins C and D have no evidence of benefit at this time. |
| Publish Date |
2021-11-17 12:02 |
| Citation |
Davis J, Umeh U, Saba R. Therapeutics for Treatment of SARS-CoV2 (COVID-19): A Safety Perspective. World J Pharmacol 2021; 10(1) 1-32 |
| URL |
https://www.wjgnet.com/2220-3192/full/v10/i1/1.htm |
| DOI |
https://dx.doi.org/10.5497/wjp.v10.i1.1 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
